Ozanimodâ–¼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...
News Medical on MSN8d
Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeuticPheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...
EDINBURGH, UK I January 14, 2025 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule ...
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, ...
PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...
Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback